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Introduction
Mutations in the BRCA1 and BRCA2 genes dramatically
increase the risk of breast cancer. Numerous mutations in
each gene have been found in most populations studied,
but only one mutation in each gene has been identified to
date in the Icelandic population of 285,000; a rare muta-
tion in the BRCA1 gene, and a much more frequent muta-
tion in the BRCA2 gene. The BRCA2 mutation (999del5)
is present in 7–8% of unselected breast cancer patients
in Iceland [1–3], and it has a much higher prevalence
(24%) in women diagnosed younger than 40 years of age
[2]. The mutation explains around 40% of the increased
breast cancer risk in first-degree relatives of Icelandic
breast cancer patients and all excess risk of prostate
cancer and ovarian cancer in relatives of breast cancer
patients [4]. The estimated breast cancer risk in mutation
carriers at the age of 70 years is 37–44% [4,5].
The two BRCA genes code for large proteins that are
involved in basic cellular functions such as DNA repair,
CDC = Cancer Detection Clinic; PCR = polymerase chain reaction.
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Abstract
Background Germline mutations in the BRCA genes dramatically
increase the risk of breast cancer. In the general population,
breast cancer risk is affected by age at menarche, by age at first
birth, by the number of births and by the duration of breast
feeding. Whether this is true for mutation carriers is not clear.
Methods  In a case–control study, nested in a population-
based cohort of the Icelandic Cancer Detection Clinic, two
groups of cases were defined, matched on year of birth, on age
at diagnosis and on age when giving information on
reproductive factors: 100 carriers of the Icelandic founder
BRCA2 mutation 999del5, and 361 BRCA2-negative cases.
The mean age at diagnosis was 48 years. There were 1000
women in a matched group of unaffected controls. Conditional
logistic regression was used for the analysis.
Results An increased number of births was associated with a
decreased risk of breast cancer in BRCA2-negative cases but
not in BRCA2-positive cases. A negative association between
risk and duration of breast feeding was observed only in the
mutation carriers. These associations were not statistically
significant, but the effects of the two variables differed
significantly according to mutation status (P = 0.007 and
P = 0.045 for interaction with number of births and with
duration of breast feeding, respectively). This was maintained
when limiting the analysis to women diagnosed older than the
age of 40 years.
Conclusion The association between breast cancer and the
number of pregnancies and between breast cancer and the
duration of breast feeding was not the same for carriers and
noncarriers of a detrimental BRCA2 mutation. In the context of
other epidemiological and laboratory studies, this may indicate
that the product of the BRCA2 gene has a function relating to
the differentiation of epithelial tissue in the breast.
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cell cycle control and transcription [6]. Why the effects of
mutations in these genes are mainly specific for cancers
that are hormonally related, such as breast cancer, ovarian
cancer and prostate cancer, is presently an important
unanswered question. There are indications that the
product of the BRCA1 gene has a role in oestrogen-
receptor signalling [7], and recent results suggest that the
BRCA2 gene may have a function relating to terminal dif-
ferentiation of breast epithelial cells [8].
An increasing age at menarche, a low age at first birth, an
increasing parity and breast feeding are associated with a
reduced risk of breast cancer in the general population
[9–12]. However, after each pregnancy there is a transient
increase in the risk of breast cancer [13–15]. The strength
and direction of the effects of pregnancies are therefore
related to time since last birth, and thus present differently
according to whether the women studied are at a fertile age
[12]. Furthermore, these associations may be affected by a
disrupted function of either of the BRCA genes [16–20]
but the picture emerging from the few studies published to
date is still far from being clear. Further studies in this field
are important as they may increase our understanding of the
function of the BRCA genes, as well as the effects of modi-
fying factors on the risk in mutation carriers.
Familial breast cancer has been extensively studied at the
Icelandic Cancer Society for more than two decades
[1,2,4,5,21–29]. The present study used information on
100 breast cancer cases carrying the Icelandic BRCA2
mutation, who were compared with breast cancer cases
without the mutation and with unaffected controls. All par-
ticipants had contributed information on reproductive risk
factors, before diagnosis of the cases, in the cohort study
of the Cancer Detection Clinic (CDC) of the Icelandic
Cancer Society. The hypothesis of the present study was
that the associations between breast cancer and age at
menarche, pregnancies and breast feeding would be dif-
ferent for women with and without the mutation.
Materials and methods
The design was a nested case–control study. Information
on reproductive factors for all participants was obtained
from the CDC cohort, where most Icelandic women
20 years or older have given answers to questions on
potential risk factors for breast cancer. These data have
been collected as a part of the nationwide, centralized cer-
vical cancer screening programme that started in 1964
and later also as a part of the nationwide breast cancer
screening that started in 1987. The questions have
changed with time; for example, information on breast
feeding has only been collected since 1979. The data-
bank is described in more detail elsewhere [12,30,31].
The number of women in the cohort to date is 98,000. A
large proportion of the women have responded to the
questionnaire on more than one occasion. The information
used in the present study was that given at the last visit
before diagnosis of the BRCA2-positive cases (and the
same year for the matched BRCA2-negative cases and
matched controls). There was a possibility of supplement-
ing missing or invalid items with information given at other
visits, concerning events that had evidently already
occurred at the last visit before diagnosis. However, analy-
ses on data corrected in this way showed that the informa-
tion for controls became considerably more complete than
for the cases, although the analyses were performed
blindly with respect to case–control status. This was
because the average number of visits to the CDC was
lower after the date of diagnosis for cases than for their
matched controls, which is probably due to their lower life
expectancy. Since this fact might have introduced a bias,
uncorrected information given at the last visit before diag-
nosis was used. Variables used in the present analysis
were age at menarche, age at first birth, number of births
and breast feeding.
All participants in the study, two case groups and controls,
belonged to the CDC cohort. Only information given
before diagnosis was used for the breast cancer cases.
The group of BRCA2-positive cases was defined using
information on mutation status for breast cancer patients
who had participated in studies of the Icelandic Cancer
Society that included collection of blood or paraffin
samples (see a further description later). The number of
mutation carriers with invasive breast cancer that had
been identified in those studies before closure of the
present study was 145. Using precoded personal identi-
fiers, record linkage with the CDC cohort resulted in 142
BRCA2-positive cases who had ever contributed informa-
tion as a part of the CDC cohort. Of these cases, 39
women were excluded because they had only given infor-
mation after diagnosis of breast cancer. For three of the
remaining 103 mutation carriers it was not possible to find
a matching case (see later), leaving 100 mutation carriers
for the analysis. They were diagnosed in the years
1967–2001.
When defining the matched group of BRCA2-negative
cases, we started with all Icelandic women diagnosed in
the period January 1965 to December 2001 (3290
women). Record linkage with the CDC cohort resulted in
2679 cases or 81% of all women diagnosed in the period.
After exclusion of women who had only given information
after diagnosis, we sought four cases from this group,
individually matched to each of the BRCA2-positive cases
on year of birth, on year of diagnosis and on year when
giving information on reproductive factors (±3 years). A
total of 1572 women fulfilled the criteria, but as only four
BRCA2-negative cases per mutation carrier were sought
and since for some of the 100 mutation carriers less thanR123
four matching women were found, this resulted in a group
of 361 BRCA2-negative cases that best matched the 100
mutation carriers. Of those cases 286 had been tested for
mutation status, leaving 75 cases with unknown status
(because they had not been participants in the later-
described studies). However, it is probably justified to
refer to the group as BRCA2-negative because, from the
earlier-defined subgroup of (1572 + 100) Icelandic breast
cancer cases, the 100 mutation carriers had already been
removed. Since 7–8% of Icelandic breast cancer patients
carry the BRCA2 founder mutation, around 125 positive
cases were expected from this subgroup. However, 100 of
those positive cases had already been removed so, among
the remaining 1572 women, only 25 carriers are expected
(1.6%). Therefore, only one or two mutation carriers are
expected among the 75 cases with unknown status.
The control group of 1000 unaffected women was drawn
from the CDC cohort with individual matching to the
BRCA2-positive cases on year of birth and on year when
contributing information. The controls had to have been
alive when their matched mutation carrier was diagnosed.
It could be of concern that the BRCA2-positive cases
might be a selected group with respect to family history,
since they were participants in earlier studies of the Ice-
landic Cancer Society. However, the majority of the group
of 100 BRCA2-positive cases (81 women) came from an
ongoing investigation inviting all cases who are alive in
Iceland. These cases are thus unselected with respect to
family history. An additional six women belonged to an
unselected group of breast cancer cases recruited in a
study on p53 mutations and risk factors using paraffin-
embedded samples. The 13 remaining women had partici-
pated in earlier studies on family history of breast cancer.
To check whether the inclusion of these cases could have
introduced a bias, a separate analysis was performed
excluding those 13 women.
The unaffected controls were not tested for mutation
status. The prevalence of the BRCA2 mutation 999del5 in
the general population is around 0.6% [2] so only six posi-
tive women were expected to be among the 1000 controls.
Odds ratios and 95% confidence intervals were estimated
applying conditional logistic regression [32]. The risk
associated with age at menarche, with parity, with age at
first birth and with total duration of breast feeding was
estimated separately for the BRCA2-positive cases and
for the BRCA2-negative cases, comparing them with con-
trols, using conditional logistic regression. This compari-
son is not likely to be invalidated by the lack of information
on mutation status in the controls since so few positive
controls were expected. Furthermore, since it was not
practical to try to estimate the effects of reproductive
factors in a carrier group of six positive individuals among
the 1000 controls, interaction between the reproductive
factors and the BRCA2 mutation status had to be tested
using a case-only approach [33] where the BRCA2-nega-
tive cases were compared with the BRCA2-positive
cases. Interaction was assumed to be present for a repro-
ductive variable if the odds ratio for that variable differed
significantly from 1.0. The analyses were performed using
STATA Statistical Software [34].
Screening for the BRCA2 999del5 germline mutation was
performed by PCR amplification and electrophoresis as
previously described [1]. All analyses were carried out on
precoded material and in full accordance with the require-
ments of the Icelandic Data Protection Authority and The
National Bioethics Committee.
Results
The mean ages at diagnosis among BRCA2-positive
cases and BRCA2-negative cases were 48.4 years (range
30–77 years) and 49.4 years (range 28–79 years),
respectively. The mean ages when the BRCA2-positive
cases,  BRCA2-negative cases and controls had con-
tributed information in the cohort study were 42.8 years
(range 21–69 years), 43.3 years (range 20–69 years) and
42.8 years (range 21–69 years), respectively. The women
were all born between 1912 and 1963 (median year of
birth was 1939), and the cases were diagnosed in the
years 1966–2001.
Table 1 compares the three groups of participants with
respect to distribution of age at menarche and reproduc-
tive variables. Also presented are percentages with
recorded responses for each item. The response rates are
similar for the three groups. They are lowest for duration of
breast feeding, due to the fact that registration of this vari-
able first started in 1979. The BRCA2-positive cases
were more likely than the controls to have given five or
more births, whereas the BRCA2-negative cases had
fewer births than the controls, as expected. The average
total duration of breast feeding was lowest in the mutation
carriers and was highest in the control group. The results
did not allow for inferences with respect to whether this
could be explained by problems with breast feeding in the
mutation carriers. A very short total duration (less than
4 weeks) or no breast feeding was less common among
parous  BRCA2-positive cases than among noncarriers
and controls, with percentages of 3.4%, 8.1% and 8.8%,
respectively. The shorter average total duration of breast
feeding in mutation carriers than in controls was mainly
due to a lower percentage with overall duration of breast
feeding for all children exceeding 2 years. When consider-
ing breast feeding for each child (data not shown), the
percentages with duration of 4 weeks or less were similar
in the mutation carriers and in controls (20.7%, 16.4%
and 21.7% for BRCA2-positive cases, noncarriers and
controls, respectively). However, BRCA2-positive cases
Available online http://breast-cancer-research.com/content/5/5/R121were less likely than controls to have breast fed each child
for longer than 6 months, with percentages being 5.2%,
12.0% and 11.9% for the affected mutation carriers, for
the cases without the mutation and for the controls,
respectively.
Table 2 presents the results from the multivariate analysis
for parous women. The effects of age at menarche and of
age at first birth were in the same direction for women
with and without the mutation, and interaction with the
mutation status was not statistically significant for these
variables. On the contrary, each additional birth was asso-
ciated with a nonsignificantly increased breast cancer risk
(17%) among the mutation carriers, whereas a marginally
significant 13% decrease in risk was observed for women
without the mutation. Interaction was present between the
mutation status and the number of births and between the
mutation status and the total duration of breast feeding
(P = 0.007 and P = 0.045, respectively). When limiting
the analysis to cases diagnosed at age 40 years or older,
the interaction was still present (P = 0.005 and P = 0.045
for the number of births and for the duration of breast
feeding, respectively). Furthermore, after exclusion of 13
mutation carriers who had been recruited because of
family history, the interaction remained statistically signifi-
cant (P = 0.005 and P = 0.021 for the number of births
and for the duration of breast feeding, respectively).
Discussion
The results indicate that there are differences between
carriers and noncarriers of a detrimental mutation in the
BRCA2 gene with respect to the association between
breast cancer risk and the number of pregnancies and
between breast cancer risk and the total duration of breast
Breast Cancer Research    Vol 5 No 5 Tryggvadottir et al
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Table 1
Comparison of age at menarche and reproductive factors between BRCA2-positive cases, BRCA2-negative cases and controls
BRCA2-positive cases (n = 100) BRCA2-negative cases (n = 361) Matched controls (n = 1000)
Risk factor % distribution Mean % distribution Mean % distribution Mean
Age at menarche n = 85 (85%)* n = 313 (87%)* n = 860 (86%)*
< 13 years 25.9 13.2 years 31.3 13.1 years 27.4 13.3 years
13 years 35.3 29.1 28.9
> 13 years 38.8 39.6 43.6
Parous n = 99 (99%) n = 355 (98%) n = 991 (99%)
Yes 89.9 88.2 93.0
No 10.0 11.8 7.0
Parous women
Age at first birth n = 85 (96%) n = 300 (96%) n = 880 (95%)
< 20 years 16.5 22.2 years 22.3 23.0 years 25.0 22.3 years
20–29 years 80.0 69.3 69.6
> 29 years 3.5 8.3 5.4
Number of births n = 89 (100%) n = 313 (100%) n = 922 (100%)
1–2 32.6 3.3 births 40.9 3.0 births 39.7 3.2 births
3–4 46.1 45.7 42.5
5+ 21.3 13.4 17.8
Total duration of breastfeeding n = 58 (65%) n = 209 (67%) n = 640 (69%)
0 months 1.7 8.5 months 2.9 9.2 months 1.9 9.3 months
< 1 months 1.7 5.3 6.9
1–6 months 44.8 37.3 38.4
7–12 months 29.3 31.1 28.8
13–24 months 19.0 18.7 17.2
> 24 months 3.4 4.8 6.9
*Percentages with recorded responses for each item.feeding. No difference was detected with respect to age
at menarche and to age at first birth.
Only relatively few studies published to date have
addressed the effects of breast cancer risk factors on
BRCA mutation carriers [7,16–19,35–39]. The majority of
these have indicated that mutation carriers respond in a
special way to breast cancer risk factors. Johannsson and
colleagues [19] found an increased risk of pregnancy-
associated breast cancer in carriers of BRCA1 mutations,
and a weaker risk in carriers of BRCA2 mutations. Jern-
strom and colleagues [16] found indications that BRCA1
mutation carriers were more likely to have problems with
breast feeding than expected. Jernstrom and colleagues
also reported [38] a positive association between breast
cancer risk and an increasing number of births in BRCA1
and BRCA2 mutation carriers. This could, however, have
been related to the low age of the cases in the study
(≤40 years at diagnosis), and thus could be explained by
the transient increase in risk following pregnancy that is
also seen in the general population [13]. Hartge and col-
leagues [18] found that mothers of carriers of BRCA1 and
BRCA2 mutations did not show the expected risk reduction
associated with lower age at first birth and with an increas-
ing number of births. In the recent study of Narod and col-
leagues [39] there was an increase in breast cancer risk in
BRCA1 mutation carriers associated with use of oral con-
traceptives, especially at young ages. No association was
present between breast cancer risk and parity in this large
group of BRCA1 and BRCA2 mutation carriers.
The present study has the advantage of using prospective
information on risk factors from a population-based cohort
for  BRCA2-positive cases, for BRCA2-negative cases
and for unaffected controls. The study group was not
restricted to young cases; the median age at diagnosis
was 48.4 years (range 30–77 years) and the interaction
between mutation status and number of pregnancies per-
sisted after excluding cases diagnosed younger than the
age of 40 years. We believe that matching on birth year
and age when responding reduced confounding and
random variation due to changes with time in reproductive
and breast feeding habits [30]. A possible bias due to
inclusion of 13 BRCA2-positive cases who were recruited
because of family history was ruled out, since the exclu-
sion of this subgroup did not affect the observed inter-
action between the mutation status and the number of
births. The present study included only carriers of one
specific BRCA2 founder mutation. However, it is probable
that inferences can be drawn for carriers of other types of
detrimental BRCA2 mutations since this mutation is a 5
base pair deletion in exon 9 leading to an early truncation
of the BRCA2 protein. On the contrary, this study pro-
vides no information regarding carriers of BRCA1 muta-
tions. The case groups were well defined but small, and
thus there was relatively low power to detect the low rela-
tive risks associated with the effects of the reproductive
variables according to earlier studies using the CDC
cohort [9,10,12,30].
The lack of a significant positive association between
breast cancer and age at first birth in the BRCA2-negative
cases was rather unexpected since such a relationship
has been confirmed in other studies based on the CDC
cohort. However, the relationship has been found to be
strongest in premenopausal cases [10,12]. The present
lack of association could thus be explained by a low
power to detect the association because there were only
245 cases in the BRCA2-negative group who were
younger than age 55 years at diagnosis. Decreased breast
cancer risk associated with breast feeding was mainly
confined to young cases in a recent Icelandic study [30].
In accordance with the present results this might be
related to the fact that 24% of breast cancer patients
diagnosed younger than age 40 years in Iceland are carri-
ers of the BRCA2 founder mutation [2].
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Table 2
Parous women: multivariate analysis of the effects of risk factors for BRCA2-positive cases and BRCA2-negative cases separately
BRCA2-positive cases (n = 100)  BRCA2-negative cases (n = 361) 
versus matched controls (n = 1000) versus matched controls (n = 1000)
Risk factor Odds ratio (95% confidence interval) P value Odds ratio (95% confidence interval) P value
Age at menarche 0.92 (0.74–1.14) 0.430 0.87 (0.77–0.99) 0.030
Age at first birth 1.01 (0.93–1.10) 0.738 1.02 (0.97–1.07) 0.352
Number of births 1.17(0.95–1.43)* 0.132 0.87(0.75–1.00)* 0.057
Total duration of breast-feeding  0.96 (0.91–1.01)** 0.141 1.01 (0.98–1.03)** 0.579
(unit, 6 months)
Odds ratios are presented per unit increment of the variables. * P = 0.007, odds ratio = 1.49 for the interaction between the number of births and
the mutation status. ** P = 0.045, odds ratio = 0.93 for the interaction between the total duration of breast feeding and the mutation status. When
testing for interaction between the other variables and the mutation status, P > 0.4.Much is still unclear about the roles of the BRCA gene
products in the biology of epithelial tissue, and explana-
tions of the tissue specificity of the effects of mutations
are lacking [40]. It is known, however, that the BRCA pro-
teins are involved in basic cellular functions such as DNA
repair, cell cycle control and transcription. More specifi-
cally, there are suggestions that the BRCA1 gene has a
role in steroid hormone signalling [6,7]. Studies of the
murine  brca1 gene indicate that it is involved in the
process of proliferation and differentiation in response to
ovarian hormones [41].
Support for a role of the BRCA1 gene relating to differen-
tiation of breast tissue in humans comes from the work of
Russo and colleagues. They have investigated the effects
of pregnancies on the differentiation of epithelial cells in
the mammary gland, both in animal models and in human
breast tissue [42–45]. The results of Russo and col-
leagues underline the importance of undifferentiated cells
in breast carcinogenesis, demonstrating their susceptibil-
ity to the effects of carcinogens contrary to differentiated
structures that are less susceptible. Furthermore, Russo
and colleagues have shown that, during the lifespan of a
female, the breast tissue undergoes complicated develop-
mental changes, and that parous women have generally
much more complex lobular structures (lobules type 3)
than nullipara (lobules type 1). In a recent study, Russo
and colleagues’ results indicated that women with a family
history of breast cancer or with BRCA1 mutations have
much less pronounced changes related to pregnancy,
suggesting that the BRCA1 gene may have a functional
role in the branching pattern of the breast during lobular
development [46].
Results of a recent study from our laboratory suggest that
the product of not only the BRCA1 gene, but also the
BRCA2 gene may have a role in the differentiation of
breast epithelial cells [8]. The protein Stat5a belongs to a
family of transcription factors that mediate the transcrip-
tional response to a diverse group of cytokines and
growth factors. Stat5a (mammary gland factor), which is
essential for growth and terminal differentiation of breast
epithelial cells and is strongly activated towards the end of
pregnancy, was shown to form a complex with BRCA1
and BRCA2 proteins in breast epithelial cells upon stimu-
lation with prolactin. Furthermore, the effects of Stat5a
were modulated by both BRCA1 and BRCA2 proteins.
The hypothesis of the present study was that the associa-
tion between breast cancer and age at menarche, preg-
nancies and breast feeding differed between women with
and without the mutation. The hypothesis was supported
for the number of pregnancies and the duration of breast
feeding. A case-only design was used for estimating the
interaction between reproductive variables and the BRCA2
mutation status. The validity of this approach has been
shown to be dependent on the assumption of indepen-
dence between the environmental and genetic factor [47].
In this study it was not possible to verify this assumption.
We could not check whether the number of children or the
duration of breast feeding was associated with the muta-
tion status because the prevalence of the mutation is very
rare in the population [2] and only six carriers were
expected among the controls. The interpretation of the
results could therefore either be that hormones associated
with pregnancies and with breast feeding affect breast
cancer risk differently in mutation carriers and in noncarri-
ers, or alternatively that mutation carriers are more likely to
have an increased number of children (i.e. be more fertile)
than other women and are more likely to present with a
short duration of breast feeding due to an inherited
reduced ability to breast feed. Even though increased fer-
tility of the mutation carriers cannot be ruled out as an
explanation for the observed association, the study by
Russo and colleagues [46] supports a function of the
BRCA1 gene in the process of differentiation as a
response to ovarian hormones. The results cited earlier,
indicating that the product of the BRCA2 gene might be
important in the process of growth and terminal differentia-
tion of breast epithelial cells, support that the same could
be true for the BRCA2 gene.
With respect to potential problems with milk production of
mutation carriers, there has been one report indicating
that this could be true [16]. In the present study, informa-
tion was not available relating to potential problems with
breast feeding. The mutation carriers were just as likely to
have ever breast fed as the other two groups, and a very
short duration of breast feeding each child was as
common among the mutation carriers as among the con-
trols. The observed lower mean duration of lactation
among the mutation carriers was due to lack of breast
feeding for more than 6 months per child. The present
results do not allow inferences to be drawn, with respect
to potential problems with breast feeding.
Conclusion
The association between breast cancer risk and the
number of pregnancies and between breast cancer risk
and the duration of breast feeding differed among women
with and without the BRCA2 mutation. The present study
does not allow for differentiating between effect modifica-
tion by mutation status on the one hand and inherited dif-
ferences with respect to fertility or problems with breast
feeding due to presence of the mutation on the other.
Further studies are needed both on fertility and potential
problems with breast feeding in unaffected mutation carri-
ers, and on the effects of hormones related to pregnancy
and breast feeding with respect to signalling and differen-
tiation in breast epithelial cells of mutation carriers. In the
context of current knowledge, however, the results are
Breast Cancer Research    Vol 5 No 5 Tryggvadottir et al
R126supportive of a hypothesis stating that the product of the
BRCA2 gene has a function relating to the differentiation
of epithelial tissue in the breast in response to the hor-
mones of pregnancy.
Competing interests
None declared.
Acknowledgements
This work was supported by grants from the US Army Medical
Research Acquisition Activity (DAMD17-97-1-7002 and DAMD17-99-
1-9216). The authors also thank the Icelandic Cancer Society for finan-
cial support, the staff of the Cancer Detection Clinic, Gudridur H
Olafsdottir, Dr Helga M Ogmundsdottir, Dr Thorvaldur Jonsson, The
Icelandic Breast Cancer Group and Iceland Genomics Corporation for
other practical support, and Sigrun Stefansdottir, Hafdis Hafsteinsdot-
tir and Holmfridur Hilmarsdottir for recruitment, sample collection and
technical work. The authors also thank three anonymous reviewers for
important comments and suggestions on a draft of this paper, and last
but not least all the women who contributed information to this study.
References
1. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonas-
son JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE:
A single BRCA2 mutation in male and female breast cancer
families from Iceland with varied cancer phenotypes. Nat
Genet 1996, 13:117-119.
2. Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonas-
son JG, Tryggvadottir L, Tulinius H, Eyfjord JE: Study of a single
BRCA2 mutation with high carrier frequency in a small popu-
lation. Am J Hum Genet 1997, 60:1079-1084.
3. Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A,
Agnarsson BA, Eiriksdottir G, Johannsson OT, Borg A, Ingvarsson
S, Easton DF, Egilsson V, Barkardottir RB: High prevalence of
the 999del5 mutation in icelandic breast and ovarian cancer
patients. Cancer Res 1996, 56:3663-3665.
4. Tulinius H, Olafsdottir GH, Sigvaldason H, Arason A, Barkardottir
RB, Egilsson V, Ogmundsdottir HM, Tryggvadottir L, Gudlaugs-
dottir S, Eyfjord JE: The effect of a single BRCA2 mutation on
cancer in Iceland. J Med Genet 2002, 39:457-462.
5. Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvalda-
son H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE: Pop-
ulation-based study of risk of breast cancer in carriers of
BRCA2 mutation. Lancet 1998, 352:1337-1339.
6. Kerr P, Ashworth A: New complexities for BRCA1 and BRCA2.
Curr Biol 2001, 11:R668-R676.
7. Narod SA: Modifiers of risk of hereditary breast and ovarian
cancer. Nat Rev Cancer 2002, 2:113-123.
8. Vidarsson H, Mikaelsdottir EK, Rafnar T, Bertwistle D, Ashworth A,
Eyfjord JE, Valgeirsdottir S: BRCA1 and BRCA2 bind Stat5a and
suppress its transcriptional activity. FEBS Lett 2002, 532:247-
252.
9. Tulinius H, Day NE, Johannesson G, Bjarnason O, Gonzales M:
Reproductive factors and risk for breast cancer in Iceland. Int
J Cancer 1978, 21:724-730.
10. Tulinius H, Sigvaldason H, Hrafnkelsson J, Olafsdottir G, Tryg-
gvadottir L, Sigurthsson K: Reproductive factors and breast
cancer risk in Iceland. A second cohort study. Int J Cancer
1990, 46:972-975.
11. Kelsey JL Gammon MD, John EM: Reproductive factors and
breast cancer. Epidemiol Rev 1993, 15:36-47.
12. Tryggvadottir L, Tulinius H, Eyfjord JE, Sigurvinsson T: Breast
cancer risk factors and age at diagnosis: an Icelandic cohort
study. Int J Cancer 2002, 98:604-608.
13. Beral V, Reeves G: Childbearing, oral contraceptive use, and
breast cancer [letter]. Lancet 1993, 341:1102.
14. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami
HO: Transient increase in the risk of breast cancer after giving
birth. N Engl J Med 1994, 331:5-9.
15. Albrektsen G, Heuch I, Kvale G: Further evidence of a dual
effect of a completed pregnancy on breast cancer risk. Cancer
Causes Control 1996, 7:487-488.
16. Jernstrom H, Johannsson O, Borg Å, Olsson H: Do BRCA1 muta-
tions affect the ability to breast-feed?: significantly shorter
length of breast feeding among BRCA1 mutation carriers
compared with their unaffected relatives. Breast 1998, 7:320-
324.
17. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber
J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod
SA: Pregnancy and risk of early breast cancer in carriers of
BRCA1 and BRCA2. Lancet 1999, 354:1846-1850.
18. Hartge P, Chatterjee N, Wacholder S, Brody LC, Tucker MA,
Struewing JP: Breast cancer risk in Ashkenazi BRCA1/2 muta-
tion carriers: effects of reproductive history. Epidemiology
2002, 13:255-261.
19. Johannsson O, Loman N, Borg A, Olsson H: Pregnancy-associ-
ated breast cancer in BRCA1 and BRCA2 germline mutation
carriers. Lancet 1998, 352:1359-1360.
20. Narod SA: Hormonal prevention of hereditary breast cancer.
Ann NY Acad Sci 2001, 952:36-43.
21. Baffoe-Bonnie AB, Beaty TH, Bailey-Wilson JE, Kiemeney LA, Sig-
valdason H, Olafsdottir G, Tryggvadottir L, Tulinius H: Genetic
epidemiology of breast cancer: segregation analysis of 389
Icelandic pedigrees. Genet Epidemiol 2000, 18:81-94.
22. Baffoe-Bonnie AB, Kiemeney LA, Beaty TH, Bailey-Wilson JE,
Schnell AH, Sigvaldason H, Olafsdottir G, Tryggvadottir L, Tulinius
H: Segregation analysis of 389 Icelandic pedigrees with breast
and prostate cancer. Genet Epidemiol 2002, 23:349-363.
23. Thorlacius S, Tryggvadottir L, Olafsdottir GH, Jonasson JG,
Ogmundsdottir HM, Tulinius H, Eyfjord JE: Linkage to BRCA2
region in hereditary male breast cancer. Lancet 1995,  346:
544-545.
24. Tryggvadottir L, Tulinius H, Robertson JM: Familial and sporadic
breast cancer cases in Iceland: a comparison related to ABO
blood groups and risk of bilateral breast cancer. Int J Cancer
1988, 42:499-501.
25. Tulinius H, Day NE, Bjarnason O, Geirsson G, Johannesson G,
Liceaga de Gonzalez MA, Sigvaldason H, Bjarnadottir G, Grims-
dottir K: Familial breast cancer in Iceland. Int J Cancer 1982,
29:365-371.
26. Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H: Risk of
prostate, ovarian, and endometrial cancer among relatives of
women with breast cancer. BMJ 1992, 305:855-857.
27. Tulinius H, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, Bjar-
nadottir K: Neoplastic diseases in families of breast cancer
patients. J Med Genet 1994, 31:618-621.
28. Tulinius H, Sigvaldason H, Olafsdottir G, Tryggvadottir L: Epi-
demiology of breast cancer in families in Iceland. J Med Genet
1992, 29:158-164.
29. Tulinius H, Sigvaldason H, Olafsdottir G, Tryggvadottir L, Bjar-
nadottir K: Breast cancer incidence and familiality in Iceland
during 75 years from 1921 to 1995. J Med Genet 1999, 36:
103-107.
30. Tryggvadottir L, Tulinius H, Eyfjord JE, Sigurvinsson T: Breast-
feeding and reduced risk of breast cancer in an Icelandic
cohort study. Am J Epidemiol 2001, 154:37-42.
31. Tryggvadottir L, Tulinius H, Larusdottir M: A decline and a halt in
mean age at menarche in Iceland. Ann Hum Biol 1994, 21:
179-186.
32. Breslow NE, Day N: Statistical Methods in Cancer Research, vol
I. The Analysis of Case–Control Studies. IARC Scientific Publica-
tions No 32. Lyon: International Agency for Research on Cancer;
1980.
33. Piegorsch WW, Weinberg CR, Taylor JA: Non-hierarchical
logistic models and case-only designs for assessing suscep-
tibility in population-based case–control studies. Stat Med
1994, 13:153-162.
34. StataCorp:  Stata Statisical Software: Release 6.0. College
Station, TX: Stata Corporation; 1999.
35. Narod SA, Goldgar D, Cannon-Albright L, Weber B, Moslehi R,
Ives E, Lenoir G, Lynch H: Risk modifiers in carriers of BRCA1
mutations. Int J Cancer 1995, 64:394-398.
36. Heimdal K, Skovlund E, Moller P: Oral contraceptives and risk of
familial breast cancer. Cancer Detect Prev 2002, 26:23-27.
37. Chang-Claude J, Becher H, Eby N, Bastert G, Wahrendorf J,
Hamann U: Modifying effect of reproductive risk factors on the
age at onset of breast cancer for German BRCA1 mutation
carriers. J Cancer Res Clin Oncol 1997, 123:272-279.
38. Jernstrom HC, Johannsson OT, Loman N, Borg A, Olsson H:
Reproductive factors in hereditary breast cancer. Breast
Cancer Res Treat 1999, 58:295-301.
Available online http://breast-cancer-research.com/content/5/5/R121
R12739. Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P,
Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C,
Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B,
Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P,
Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner
E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver
S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS: Oral contra-
ceptives and the risk of breast cancer in BRCA1 and BRCA2
mutation carriers. J Natl Cancer Inst 2002, 94:1773-1779.
40. Venkitaraman AR: Cancer susceptibility and the functions of
BRCA1 and BRCA2. Cell 2002, 108:171-182.
41. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ,
Weber BL, Chodosh LA: The developmental pattern of Brca1
expression implies a role in differentiation of the breast and
other tissues. Nat Genet 1995, 11:17-26.
42. Russo IH, Russo J: Developmental stage of the rat mammary
gland as determinant of its susceptibility to 7,12-dimethyl-
benz[a]anthracene. J Natl Cancer Inst 1978, 61:1439-1449.
43. Russo J, Rivera R, Russo IH: Influence of age and parity on the
development of the human breast. Breast Cancer Res Treat
1992, 23:211-218.
44. Russo J, Russo IH: Cellular basis of breast cancer susceptibil-
ity. Oncol Res 1999, 11:169-178.
45. Russo J, Tay LK, Russo IH: Differentiation of the mammary
gland and susceptibility to carcinogenesis. Breast Cancer Res
Treat 1982, 2:5-73.
46. Russo J, Lynch H, Russo IH: Mammary gland architecture as a
determining factor in the susceptibility of the human breast to
cancer. Breast J 2001, 7:278-291.
47. Albert PS, Ratnasinghe D, Tangrea J, Wacholder S: Limitations
of the case-only design for identifying gene–environment
interactions. Am J Epidemiol 2001, 154:687-693.
Correspondence
Laufey Tryggvadóttir, Icelandic Cancer Registry, Skógarhlíð 8, P.O. Box
5420, IS-125 Reykjavík, Iceland. Tel: +354 540 1900; fax: +354 540
1910; e-mail laufeyt@krabb.is
Breast Cancer Research    Vol 5 No 5 Tryggvadottir et al
R128